

Saskatchewan Immunization Manual Amendments February 2020

Instructions: Please remove and discard the corresponding pages in each chapter section as applicable and insert the amended pages as noted below in each corresponding chapter section dated **February 2020**.

Chapter 1 Introduction

- P. 11 School Immunization Programs
 - MMRV section updated as no longer offered to those 13 years and older as of the 19-20 school year.
- P. 12 Appendix 5.2 Hx of Publicly Funded Programs
 - New addition to HB – 2012 - 0.25 mL series no longer accepted for infants/children, all to receive 0.5 ml/dose to complete series.
- P. 14 Appendix 5.2 Hx of Publicly Funded Programs
 - Update to MMRV row – 2012/13 to 2018/19 - MMRV approved for Grade 6 students 13 years and older until they began their Grade 7 school year.
 - Update to Pneumococcal vaccine row dated March 16, 2015 – now states, “Pneu-P-23 booster dose ...”

Chapter 5 – Immunization Schedules

- TOC page 2 Section 4.4
 - Dose changed to Dosage as that is the content of the paragraph
- P. 4 Section 1.3B Pneumo Schedule for Medically High Risk Children
 - Third bullet Pneu-P-13 corrected to Pneu-C-13.
- P. 6 Section 1.5 Children 7 to 17 Years Who Present for Immunizations
 - Footnote 2 – Reference to footnote 15 changes to footnote 13.
- P. 22 Section 4.3 Individuals Who Received a Vaccine by a Route Other than that Recommended
 - “... appropriate injectable influenza vaccine added to vaccines that must be given IM to be considered valid”, added to second last sentence.
- P. 28 of Appendix 5.2
 - The following noted have been added:

Notes:

1. Infants 6-11 months old **do not need MMR** if they are travelling to or within the countries listed above.
2. Travelling infants 6 months to younger than 12 months of age **may** be offered an early publicly funded dose of MMR vaccine if they are travelling to:
 - Mass gatherings (generally defined of $\geq 25,000$ people according to the WHO) of international travellers (e.g., sporting events, pilgrimages, etc.) anywhere in the world; or
 - Countries outside of Canada, the United States of America (including Hawaii), Mexico and most Caribbean countries.

Chapter 7 – Special Populations

- Pp. 19-20 Section 3.7 Medical Treatment
 - The following statement added to page 19 under Inactivated Vaccines and as Footnote 2 to Table 3.7A: The third dose of Pneu-C-13 vaccine that forecasts at 6 months of age is unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.
- Pp. 34 and 36 Appendix 7.1
 - Foot 2 is now footnote 2B
 - New footnote 2B added to Treatment – Additional Information risk factor and footnote table: The third dose of Pneu-C-13 vaccine that forecasts at 6 months of age is unnecessary for infants whose mothers took monoclonal antibody medications while pregnant.

Saskatchewan Immunization Manual Amendments February 2020

Chapter 8 – Administration of Biological Products

- P. 1 Section 1.1.1 General Screening questions
 - #6 amended and references to TB skin test and 6 weeks have been removed.
- P. 6 section 1.4.1 Practice Considerations
 - Brand names removed from section.
 - Second bullet now reads, (e.g., give DTaP-IPV-Hib first, followed by MMRV and then Pneu-C-13).
- P. 7 section 1.5 Publicly Funded Immunizations Following Non-Conforming Situations
 - Oral vaccine added under live vaccine section.

Chapter 10 Biological Products

- TOC page 1 section title change
 - Hepatitis B Series Completion Recommendations for Children Younger 11-15 Years Old
- INFANRIX-IPV/Hib and Pediacel
 - New footnote #5: Maximum age for administration is 6 years old unless medically indicated for those 7 years and older such as transplant patients.
- Hepatitis B Series Completion Recommendations for Children Younger 11-15 Years Old
 - New bullet #3: Applies to students in Grade 6 who are younger than 11 years old.
- Gardasil 9 – new 2020 Product monograph
 - Under first and second indications, up to and including 26 years of age added.
 - New under indications: Individuals who are eligible to receive publically funded HPV vaccine must start their series prior to the age of 27. If first dose is given prior to age of 27 then subsequent publicly funded doses can be given to complete series after this age. If series is not started before 27th birthday, they are ineligible to start a publicly funded series.
 - New Note row added (under Reinforcement): GARDASIL[®]9 should be used to complete an HPV series that was initiated with HPV-u, HPV-2 or HPV-4. Clients should be informed that a complete series of GARDASIL[®]9 is recommended to ensure protection against the five additional HPV types in the vaccine; however, additional doses of GARDASIL[®]9 beyond a complete HPV series for healthy or immune compromised individuals are not part of the publicly-funded program.
- Priorix-Tetra and ProQuad MMRV vaccines
 - Third indication now reads Grade 6 students < 13 years old.
- Menveo and Nimenrix
 - 6 weeks is the minimum age for these vaccines in the indications.
- Prevnar 13
 - New scenarios added to reflect those presented in SIM Chapter 5 sections 1.3A and 1.3B. Please have staff review.
 - Footnote # 1 now states' "If series is interrupted, complete series according to age at which child re-presents using minimum intervals as noted in SIM Chapter 5 Section 2.1 Minimum intervals for Specific Vaccines. Refer ..."
 - New footnote #5: Children up to and including 17 years old who have previously received Pneu-P-23 should received the recommended Pneu-C-13 doses.
- IPV
 - New footnote #2: Dose 3 must be given 6 months after dose 2 and at least after 1 year of age.
- Adacel and Boostrix,
 - The following added to select scenarios in Section 8B: (must be given ≥ 4 years old).
- Adacel-Polio and Boostrix-Polio
 - The following added to select scenarios in Section 3B: (must be given ≥ 4 years old).

Saskatchewan Immunization Manual Amendments February 2020

Chapter 11 Adverse Events Following Immunization

- P. 7 Section 3.2
 - [Web links to PHAC AEFI form and User Guide have been updated.](#)
- P. 8 Section 3.3
 - [Web link to AEFI User Guide updated.](#)
- P. 13 Appendices
 - [Web links to PHAC AEFI form and User Guide have been updated for Appendices 11.2 and 11.3 respectively.](#)

Chapter 14 Appendices

- Added: [Forecasting Third Dose of Pneumococcal Conjugate 13 Vaccine is Unnecessary for Infants Whose Mothers took Monoclonal Antibodies during Pregnancy from 2020-01-08](#)